A phase I study of lenalidomide plus chemotherapy with idarubicin and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high‐risk myelodysplastic syndrome

Patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) have poor outcomes and hematopoietic cell transplantation (HCT) is the only curative treatment. New targeted therapies improved survival in select patients with specific mutations, however management of patients without these molec...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Am J Hematol
Main Authors: Saygin, Caner, Larkin, Karilyn, Blachly, James S., Orwick, Shelley, Ngankeu, Apollinaire, Gregory, Charles T., Phelps, Mitch A., Mani, Shylaja, Walker, Alison, Garzon, Ramiro, Vasu, Sumithira, Walsh, Katherine J., Bhatnagar, Bhavana, Klisovic, Rebecca B., Grever, Michael R., Marcucci, Guido, Byrd, John C., Blum, William, Mims, Alice S.
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley & Sons, Inc. 2020
Assuntos:
Research Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7821016/
https://ncbi.nlm.nih.gov/pubmed/32777116
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ajh.25958
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados